C4 Therapeutics Inc (CCCC) Stock Price, Quote & News

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BR...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 231 0700

Website: www.c4therapeutics.com

Address:

490 Arsenal Way, Suite120, Watertown, United States

AtomicAIerts Dec. 5 at 11:59 AM

$CCCC AtomicAlerts Scalp Alert Direction: SHORT Entry: $2.6 TP1: $1.9 | TP2: $1.2 | TP3: $0.5 Stop Loss: $3.2 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 6:33 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CCCC Contract: Dec 19 $3C Entry: 0.47 Exit: 0.75 Return: +58.23% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 5 at 12:22 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CCCC Contract: Dec 19 $3C Entry: 0.47 Exit: 0.75 Return: +58.23% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BiotechBonesaw Dec. 4 at 6:54 PM

$ALT $CCCC $IXHL $TNXP woah 👀 this news is MAJOR! Get your popcorn ready 🍿 https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/

2 · Reply

pchr Dec. 4 at 9:08 AM

$CCCC very pretty chart, can get explosive

0 · Reply

Iightning Dec. 4 at 8:00 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CCCC Contract: Dec 19 $3C Entry: 0.70 Exit: 1.08 Return: +54.02% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

josegodoy Dec. 4 at 6:46 AM

$CCCC - the chart has been suggesting significant upside (to me) - recent occurrences seem to confirm upside potential - the specific catalyst: 🤷‍♂️ Using $2.50 as a “merged jump off point” I can argue for - $3.06 to $3.96 (as side from recent occurrences: $3.50-ish is a calculated value that has come up) Pattern based trading - $3.37 (as transient target) - true Upside price target remains: $5-$6 Will it happen?….. I don’t know (88% = YES) An opinion (you play how you feel it)

1 · Reply

QuantInsider Dec. 4 at 4:05 AM

$CCCC with a wild ride today Big +16% move catching eyes Aggressive Dec 19 $3 call sweeps went off with 2,462, 1,885, and 614 contracts That's way above existing OI of 1,128 Strong signal for upside into OPEX Also saw a $97K buy of Dec 19 $2 ITM calls near the close High delta and opening exposure show serious conviction in more upside Shares popping +15.6% today, momentum is real IV on active strikes hit around 170 to 290% Watch those options, pricey but could keep pushing Stay sharp around $3

0 · Reply

Andysss Dec. 4 at 2:18 AM

$CCCC still trades near book value with minimal pipeline premium. Not trading this. Holding trough «near tem» goal. Don’t let swings shake u off. Remember who bought

0 · Reply

S2K_TP Dec. 4 at 1:21 AM

$CCCC on watch 👀

0 · Reply

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

Nov 25, 2025, 7:00 AM EST - 10 days ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 10:16 AM EST - 22 days ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

CWST ESPR INSP MNDY SITM

Nov 6, 2025, 7:00 AM EST - 4 weeks ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 16, 2025, 7:08 AM EDT - 7 weeks ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma$

Oct 1, 2025, 7:00 AM EDT - 2 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Sep 22, 2025, 5:23 AM EDT - 2 months ago

C4 Therapeutics, Inc. - Special Call

Sep 20, 2025, 11:00 AM EDT - 2 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 15, 2025, 6:33 PM EDT - 2 months ago

Why C4 Therapeutics Stock Crushed the Market on Monday

Sep 4, 2025, 7:00 AM EDT - 3 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 3, 2025, 7:00 AM EDT - 3 months ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Aug 7, 2025, 10:46 AM EDT - 4 months ago

CCCC Revenue Drops 46%

Aug 7, 2025, 7:00 AM EDT - 4 months ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 16, 2025, 1:50 PM EDT - 6 months ago

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

May 7, 2025, 7:00 AM EDT - 7 months ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 10 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 24, 2025, 7:00 AM EST - 10 months ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Oct 28, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jun 10, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

May 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 8, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 1 year ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 22, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

$C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma$

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma$

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession

Aug 8, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 15, 2023, 1:58 AM EDT - 2 years ago

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 5, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

Jun 20, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

AtomicAIerts Dec. 5 at 11:59 AM

$CCCC AtomicAlerts Scalp Alert Direction: SHORT Entry: $2.6 TP1: $1.9 | TP2: $1.2 | TP3: $0.5 Stop Loss: $3.2 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 6:33 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CCCC Contract: Dec 19 $3C Entry: 0.47 Exit: 0.75 Return: +58.23% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 5 at 12:22 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CCCC Contract: Dec 19 $3C Entry: 0.47 Exit: 0.75 Return: +58.23% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BiotechBonesaw Dec. 4 at 6:54 PM

$ALT $CCCC $IXHL $TNXP woah 👀 this news is MAJOR! Get your popcorn ready 🍿 https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/

2 · Reply

pchr Dec. 4 at 9:08 AM

$CCCC very pretty chart, can get explosive

0 · Reply

Iightning Dec. 4 at 8:00 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CCCC Contract: Dec 19 $3C Entry: 0.70 Exit: 1.08 Return: +54.02% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

josegodoy Dec. 4 at 6:46 AM

1 · Reply

QuantInsider Dec. 4 at 4:05 AM

0 · Reply

Andysss Dec. 4 at 2:18 AM

$CCCC still trades near book value with minimal pipeline premium. Not trading this. Holding trough «near tem» goal. Don’t let swings shake u off. Remember who bought

0 · Reply

S2K_TP Dec. 4 at 1:21 AM

$CCCC on watch 👀

0 · Reply

BiotechBonesaw Dec. 4 at 12:43 AM

$CCCC is one of my favorite long holds 💪

0 · Reply

LabPsycho Dec. 4 at 12:10 AM

$CCCC @BioRich If I am reading the options correctly, 30K+ options Dec 19 $3 calls - 65 cents...but maybe that was the price for a few at the last couple of trades. Otherwise makes little sense to me - stock would have to go up 40% just to break even...very high risk...seems the stock would be a better risk / reward ratio, unless someone thinks this is going to $5+ in 2 weeks.

1 · Reply

RonIsWrong Dec. 3 at 11:59 PM

$CCCC end of the day numbers let's check the OI tomorrow though as profits were available on those calls already.

1 · Reply

carrotcarrot Dec. 3 at 11:25 PM

$CCCC WHY???!?!

1 · Reply

Sw1ngb0t Dec. 3 at 10:28 PM

$PHVS $CCCC $GOSS $ERAS some newbs

0 · Reply

BiotechBonesaw Dec. 3 at 9:38 PM

$CCCC still dirt cheap 📊 and blood cancer patients are waiting ⏰

0 · Reply

pchr Dec. 3 at 9:18 PM

$CCCC had a lovely swing from the lows in the summer and just jumped back in at 2.59. Ang incoming catalysts? What’s the bull thesis now? Saw point72 adding 21mln shares which is always a good sign

0 · Reply

BioRich Dec. 3 at 8:52 PM

$CCCC Just started my position. C4 about to blow up! Corny, I know, but I dig what I'm seeing with the options. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money! Cheers!

1 · Reply

bassman4444 Dec. 3 at 8:43 PM

$CCCC When is Data getting released? Does anyone know?

1 · Reply

RonIsWrong Dec. 3 at 7:56 PM

$CCCC 👀 huh volume spike because of 30000 calls with around a 49 delta or so almost 1.5M shares for the MM to buy

3 · Reply

zawojak Dec. 3 at 7:56 PM

$CCCC is

0 · Reply

vu_jade Dec. 3 at 7:54 PM

$CCCC 2026 will be awesome

0 · Reply

Market Cap	235.50M
Revenue (ttm)	35.58M
Net Income (ttm)	-105.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-296.01%
Debt to Equity Ratio	0.00

Volume	3,014,500
Avg Vol	2,050,664
Day's Range	N/A - N/A
Shares Out	96.91M
Stochastic %K	95%
Beta	2.87
Analysts	Strong Sell
Price Target	$11.86